[email protected]
CDI - Contrive Datum Insights
Healthcare Services

Genomics Services Market Size, Growth Rate and Forecast to 2034: Drivers, Risks and Regional Share

Genomics services revenue runs from USD 14 billion in 2025 to USD 36.6 billion in 2034 at an 11.12% CAGR, with North America at 41% and sequencing services at 46% of revenue.

Published: Industry: Healthcare ServicesRead time: ~5 min

The genomics services market stood at USD 14 billion in 2025. The forecast takes it to USD 36.6 billion by 2034, a CAGR of 11.12% across 2026 to 2034. This article sets out what that rate rests on, what could pull the outcome above or below it, and where the revenue sits by region and service type.

Market size and growth rate

The record before the forecast is a strong one. Revenue was USD 7.2 billion in 2020 and USD 12.4 billion in 2024, a historical period that compounded at 14.22%. The 2025 figure of USD 14 billion is the base year for every scenario in the study.

The forecast rate is lower than the historical one, and it is applied evenly. No ramp is built in: 11.12% runs across the whole period. A forecast that extends an observed trend is a different proposition from one that proposes a turn, and this one extends the trend at a slower pace.

Two alternative cases bracket the base case. The bear case reaches USD 29.5 billion in 2034 and the bull case reaches USD 42 billion. Both start from the same USD 14 billion in 2025. The spread between them comes from assumptions about reimbursement, pricing and outsourcing, covered below.

What is driving it

The headline rate is a weighted result. No single service line grows at 11.12%, so the market rate depends on which lines carry the growth.

Epigenomics Services is the line that carries it. It grows at 15.29% against 11.12% for the market, moving from USD 0.7 billion in 2025 to USD 2.56 billion in 2034. Its share of revenue moves from 5% to 7%. Sanger Sequencing Services grows at 2.48% on the same axis. A supplier's position on the service type axis therefore decides whether it grows with the market or below it.

The second driver is the location of existing revenue. North America holds USD 5.74 billion in 2025, 41% of the global total, and reaches USD 13.18 billion by 2034 at 36%. Europe is next at 27% of revenue, with USD 3.78 billion in 2025 and USD 9.15 billion in 2034. Because both the base and the added revenue concentrate in these two regions, regional weighting matters more to a forecast than regional count does.

The third driver is the historical trend itself. Demand grew at 14.22% before the forecast window opens, and the forecast assumes a slower continuation, not a reversal. Readers tracking adjacent healthcare services can compare this profile with the telemedicine market, which the same research programme sizes at USD 572.35 billion by 2034 at a 17% CAGR, and where one service line also carries the blended rate.

What could slow it

The bear case is the clearest statement of the risk. It puts 2034 revenue at USD 29.5 billion against USD 36.6 billion in the base case. It rests on one stated assumption with three parts: reimbursement stalls, data localisation rules push work in-house or in-region, and academic funding stays weak. Volume growth then slows, and prices fall faster than volumes rise. The USD 14 billion 2025 base does not change in either case.

Two structural features of the market add to this exposure.

  • **Microarray Services is a drag on the average.** It holds 9% of 2025 revenue at USD 1.26 billion and grows at only 3.88% against the market's 11.12%. Revenue still reaches USD 1.83 billion by 2034, but its share falls to 5%. That is a drag on the average and not a decline.
  • **One service type carries the market.** Next-Generation Sequencing Services is 46% of 2025 revenue at USD 6.44 billion and still 50% at USD 18.3 billion in 2034. A market leaning this heavily on one line concentrates its exposure there. A shift in demand for that line moves the total more than any other single change on the axis.

A third point sits inside the regional data. The United States generates USD 5.14 billion of North America's USD 5.74 billion in 2025, which is 89.55% of the region, and reaches USD 11.7 billion by 2034. A regional number that depends this heavily on one country carries that country's specific conditions inside it. A reader treating North America as diversified would miss that.

The upside case runs on the opposite assumptions. Sequencing prices fall faster and unlock larger volumes, reimbursement for genomic tests broadens, and national genome programs outsource more work to commercial providers. That combination gives the USD 42 billion bull case. Pricing and reimbursement exposure is also visible in the behavioral health market, another healthcare services study where payer decisions shape the forecast, and where North America also holds 41% of global revenue.

Where the growth sits

**By region.** North America leads with 41% of global revenue, ahead of Europe at 27% and Asia Pacific at 24%. Latin America holds 5% and the Middle East and Africa 3%. North America's share eases to 36% by 2034 while its revenue still rises to USD 13.18 billion.

**By service type.** The service type shares for 2025 are:

  • Next-Generation Sequencing Services: 46%
  • Bioinformatics and Data Analysis Services: 17%
  • Microarray Services: 9%
  • Sanger Sequencing Services: 8%
  • Genotyping Services: 8%
  • Other Genomics Services: 7%
  • Epigenomics Services: 5%

Bioinformatics and Data Analysis Services is the second largest line at 17%, behind sequencing by a wide margin. Epigenomics Services is the smallest named line and the fastest growing, which is why its move from 5% to 7% matters to the total. Taking position there does not require displacing whoever holds Next-Generation Sequencing Services, the harder and more expensive fight.

The study cuts the market eleven ways beyond service type, including sequencing technology, application, workflow stage, end user, sample type, disease area and project scale. The application axis runs from research and clinical diagnostics to drug discovery, precision medicine, agriculture and consumer genomics. Buyers weighing a home-delivered clinical service against a laboratory one will find a parallel in the home infusion therapy market, sized at USD 82.96 billion by 2034 at an 8% CAGR, where again a single specialty line carries the blended rate.

For the full segmentation, the scenario assumptions and the country detail behind the regional figures, see the genomics services market report page.